Actimed Therapeutics Secures Additional £4.75M Funding in Series a Extension Round, Almost Doubling Series a Proceeds

The proceeds will be used to fund the continued development of the company and will ensure that preparations remain on track for the global Phase IIb/III IMPACT clinical development program evaluating its lead asset, S-pindolol benzoate in treating cachexia associated with non-small cell lung cancer and colorectal cancer.